AstraZeneca today announced the US Food and Drug Administration has accepted a supplemental New Drug Application and granted Priority Review for BRILINTA for the reduction of subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack. The Prescription Drug User Fee Act date, the FDA action date for this...
AstraZeneca Plc (AZN.L) Announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Brilinta (ticagrelor) for the reduction of subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack (TIA). #AZN
RNS Number: 5186 S AstraZeneca PLC 09 July 2020 9 July 2020 07:00 BST. Brilinta granted FDA Priority Review for the reduction of subsequent stroke in patients who had an acute ischemic stroke or transient ischemic attack. Brilinta in combination with aspirin could be the first FDA-approved dual antiplatelet therapy to reduce the rate of stroke in these...
AstraZeneca Plc (AZN.L) Announced that Lynparza (olaparib) has been approved in the European Union (EU) for patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. The approval by the European Commission was based on results from the Phase III POLO trial.v #AZN
RNS Number: 3706 S AstraZeneca PLC 08 July 2020 8 July 2020 07:00 BST. Lynparza approved in the EU for BRCA- mutated metastatic pancreatic cancer. AstraZeneca and MSD Inc., Kenilworth, N.J., US today announced that Lynparza has been approved in the European Union for patients with germline BRCA-mutated metastatic pancreatic cancer.
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6. 1. As at 30 June 2020 the issued share capital of AstraZeneca PLC with voting rights is 1,312,271,081 ordinary shares of US $0.25. The above figure for the total number of voting rights may be used by shareholders as the denominator...
RNS Number: 5565 R AstraZeneca PLC 30 June 2020 30 June 2020 15:00 BST. AstraZeneca PLC announces that, on 29 June 2020, it was notified by Pascal Soriot, Chief Executive Officer, that, on 29 June 2020, Mr Soriot ceased to be beneficially interested in 127,389 Ordinary Shares of $0.25 each in the Company, following the gift of those shares to family members for nil...
AstraZeneca Plc (AZN.L) Announced that selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1), a rare and debilitating genetic disease. Selumetinib is co- developed and co-commercialised with MSD Inc., Kenilworth, N.J., US. #AZN
Full results from the positive Phase III ETHOS trial showed AstraZeneca’ s triple-combination therapy PT010 demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe chronic obstructive pulmonary disease.
RNS Number: 2547 Q AstraZeneca PLC 17 June 2020. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 2539 Q AstraZeneca PLC 17 June 2020. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
AstraZeneca to supply Europe with up to 400 million. AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance, spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford's COVID-19 vaccine, with deliveries starting by the end of 2020.. The IVA is committed to providing...
AstraZeneca Plc (AZN.L) Announced that Base Prospectus for the AstraZeneca PLC U.S. $10,000,000,000 Euro Medium Term Note Programme has been approved by the Financial Conduct Authority and is available for viewing. The last drawdown under the EMTN programme was in 2016. #AZN
AstraZeneca will present new data from the landmark Phase III DAPA-HF and DECLARE-TIMI 58 trials at the upcoming 80 th American Diabetes Association Virtual Scientific Sessions, June 12– 16 2020. The data are among 23 accepted abstracts, including four oral presentations, covering trials that showcase the depth and breadth of potential cardio, renal and...
RNS Number: 6000 P AstraZeneca PLC 11 June 2020 11 June 2020 07:00 BST. Base Prospectus for the AstraZeneca PLC U.S. $10,000,000,000 Euro Medium Term Note Programme.. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Accent Therapeutics and AstraZeneca will collaborate to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins for the treatment of cancer. The collaboration combines Accent’ s expertise as a leader in the biology, target identification and drug discovery of RMP-targeting therapies with AstraZeneca’ s...
AstraZeneca Plc
AZN.L
AstraZeneca Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    1.31B

Income Statement

Sales/Revenue
Gross Income
Operating Income
Net Interest Income
Pre-Tax Income
Consolidated Net Income
Non-Interest Income
Interest Income after Loan Loss Provision
Non-Operating Income
Operating Income (EBIT)
Net Income
Non-Interest Expense
Operating Expenses
Total Expense
Operating profit per share
EPS (Basic)
EPS (Diluted - Before Unusual Expense)
EPS (Fully Diluted)

Balance Sheet - Assets

Net Property, Plant & Equipment
Intangible Assets
Cash & Short Term Investments
Investments
Other Financial Assets
Inventories
Total Short Term Accounts Receivable
Total Accounts Receivable
Total Cash & Due from Banks
Premium Balance Receivables
Total Current Assets
Tangible Other Assets
Other Intangible Assets
Other Assets
Other Funds
Total Assets

Balance Sheet - Liabilities

Liabilities & Stockholders' Equity
Other Current Liabilities
Total Current Liabilities
Provision for Risks & Charges
Losses, Claims & Reserves
Other Liabilities
Total Liabilities

Balance Sheet - Other

Dividends Per Share (Gross)
Dividends Per Share
Dividends Per Share (1-yr Annual Growth)
Dividend payout per share
Common Shares
Common Shares Outstanding
Common Shares (EPS Basic)
Common Shares (EPS Diluted)
Closely Held Shares
Total Shareholders' Equity
Non-Equity Reserves
Retained Earnings
Total Equity
Pre-Tax Margin
Net Interest Margin
Gross Profit Margin
Net Margin
Operating Margin
P/E Ratio
Debt / EBITDA
Total Debt / Assets
Assets Per Employee
Current Ratio
Common Stock Par / Carry Value
Enterprise Value
Market Value
Market Capitalisation
Dividend Yield
Dividend Yield - Security
Cash Dividend Coverage Ratio

Miscellaneous

Total Debt
Restricted Cash
Exchange Rate Effect
Incomes Taxes
Net Change in Cash
Income Tax Payable
Cash Only
Cash Dividends Paid
Convertible Debt
Long Term Debt
Short Term Debt
Asset Turnover
EBITDA
Operating Income After Interest Expense
Net Debt
Operating Income Before Interest Expense
Purchase / Sale of Investments
Other Appropriated Reserves
Creditors
Watchlist